Abstract
Nigrostriatal dopamine (DA)-containing neurones have the potential to modulate neostriatal output at two levels. First, DA released from the terminals of the DA-containing pars compacta neurones can act on striatal DA receptors. In addition, these pars compacta cells can release DA from their dendrites within the nigra1–3. Dendritically released DA could act at receptors located on these same cells (‘autoreceptors’)4,5 or at receptors which are located on other nigral elements, especially strionigral afferent fibres4,6,7. However, although the stimulation of striatal DA receptors produces clear behavioural effects, no behavioural consequence of nigral DA receptor stimulation has been shown8,9. We report here that nigral DA receptor stimulation can produce clear behavioural effects in the appropriate circumstances. Unilateral intranigral injections of the DA receptor stimulant, apomorphine, produce clear contralateral turning in animals that (1) had been previously given intracerebral 6-hydroxydopamine (6-OHDA) injections, which extensively damage the ipsilateral nigral DA-containing cells, or (2) had been pretreated for 1 week with the DA receptor blocker, haloperidol. In addition, the turning produced by intranigral apomorphine in 6-OHDA-treated animals was much greater when the drug was given 14–17 days after the intracerebral neurotoxin than when it was given 4–7 days after, suggesting the development of supersensitivity to apomorphine in the nigra. These results suggest that the nigra must be considered as a site of action for drugs whose main effect is on the dopaminergic system.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Björklund, A. & Lindvall, O. Brain Res. 83, 531–537 (1975).
Nieoullon, A., Cheramy, A. & Glowinski, J. Nature 266, 375–377 (1977).
Hefti, F. & Lichtensteiger, W. J. Neurochem. 30, 1217–1230 (1978).
Groves, P. M., Wilson, C. W., Young, S. J. & Rebec, G. V. Science 190, 522–529 (1975).
Aghajanian, G. K. & Bunney, B. S. Adv. Biochem. Pharmac. 16, 433–438 (1977).
Gale, K., Hong, J.-S. & Guidotti, A. Brain Res. 136, 371–375 (1977).
McGeer, P. L., McGeer, E. G. & Innanen, V. T. Brain Res. 169, 433–441 (1979).
Glick, S. D. & Crane, L. A. Brain Res. 156, 380–381 (1978).
Kelley, P. Y. & Moore, K. E. Neuropharmacology 17, 169–174 (1978).
Gianutsos, G., Drawbaugh, R. B., Haynes, M. D. & Lal, H. Life Sci. 14, 887–898 (1974).
Von Voigtlander, P. F. Fedn Proc. 33, 578 (1974).
König, J. F. R. & Klippel, R. A. The Rat Brain: A Stereotoxic Atlas of the Forebrain and Lower Parts of the Brain Stem (Krieger, New York, 1963).
Gale, K., Guidotti, A. & Costa, E. Science 195, 503–505 (1977).
Jessell, T. M., Emson, P. C., Paxinos, G. & Cuello, A. C. Brain Res. 152, 487–498 (1978).
Quick, M., Emson, P. C. & Joyce, E. Brain Res. 167, 355–365 (1979).
Garcia-Munoz, M., Nicolaou, N. M., Tulloch, I. F., Wright, A. K. & Arbuthnott, G. W. Nature 265, 363–365 (1977).
Reubi, J.-C., Iversen, L. L. & Jessell, T. M. Adv. Biochem. Psychopharmac. 19, 401–404 (1978).
Olianas, M. C., DeMontis, G. M., Mulas, G. & Tagliamonte, A. Eur. J. Pharmac. 49, 233–241 (1978).
diChiara, G., Porceddu, M. L., Morelli, M., Mulas, M. L. & Gessa, G. L. Naunyn-Schmiedebergs Archs Pharmak. 306, 153–159 (1979).
Ungerstedt, U., Butcher, L. L., Butcher, S. G., Andèn, N.-E. & Fuxe, K. Brain Res. 14, 461–471 (1969).
Marshall, J. F. & Ungerstedt, U. Science 198, 62–64 (1977).
Ungerstedt, U. Acta physiol. scand. Suppl. 367, 69–93 (1971).
Thornburg, J. E. & Moore, K. E. J. Pharmac. exp. Ther. 192, 42–49 (1975).
Nagy, J. I., Lee, T., Seeman, P. & Fibiger, H. C. Nature 274, 278–281 (1978).
Creese, I., Burt, D. R. & Snyder, S. H. Science 197, 596–598 (1977).
Gale, K. Neurosci. Abstr. 5, 71 (1979).
Gale, K. Nature 283, 569–570 (1980).
Stricker, E. M. & Zigmond, M. J. Progress in Physiological Psychology and Psychobiology Vol. 6 (eds Sprague, J. M. & Epstein, A. M.) 121–180 (Academic, New York, 1976).
Marshall, J. F. Brain Res. 177, 311–324 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kozlowski, M., Sawyer, S. & Marshall, J. Behavioural effects and supersensitivity following nigral dopamine receptor stimulation. Nature 287, 52–54 (1980). https://doi.org/10.1038/287052a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/287052a0
This article is cited by
-
Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting
Experimental Brain Research (1991)
-
Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats
Psychopharmacology (1985)
-
Dissociation between circling behaviour and striatal dopamine activity following unilateral deltamethrin administration to rats
Naunyn-Schmiedeberg's Archives of Pharmacology (1985)
-
Dopaminergic D-3 binding sites are not presynaptic autoreceptors
Nature (1983)
-
The effects of dose and duration of chronic pimozide adminstration on dopamine receptor supersensitivity
Naunyn-Schmiedeberg's Archives of Pharmacology (1983)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.